Featured News

Concern has been expressed in the celiac disease community that the FDA’s temporary food labeling requirements during COVID-19 apply to gluten. The FDA confirmed that the introduction of unlabeled gluten is not allowed in regulated food products.

We are pleased to announce our newest online resource for patients and caregivers to drive policy change to improve the health of those living with celiac disease and accelerate research: iAdvocate.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

Each year, we proudly embrace the unity and generosity of our community during May Celiac Disease Awareness Month.

On Friday, I joined three of the leading celiac disease researchers in the world to present to the NIH’s Autoimmune Disease Coordinating Committee (ADCC) the findings from the CDF-sponsored First SSCD Consensus Workshop: Research Opportunities in Celiac Disease 2020.

Today is the last day to receive delicious Schar goodies in exchange for a donation to the Celiac Disease Foundation! Join us in generating funds for research for treatments and a cure.

We have been hearing from our community about COVID-19 and celiac disease and about our work at the Celiac Disease Foundation during the pandemic. We have answered the most frequently asked questions in a short video for you. 

People with celiac disease have a 10-fold greater risk for inflammatory bowel disease (IBD). Those with IBD have a 4-fold greater risk for celiac disease. A new study reviews the link between these two autoimmune disorders.

The Voluntary Recommendations for Managing Celiac Disease in Learning Environments provides definitive guidance for schools, parents and caregivers for 504 accommodations for children with celiac disease. Download the guide and watch the video.

TAK-062, an orally administered synthetic enzyme that survives the acidity of the stomach and digests gluten effectively, has passed its phase 1 clinical drug trial, indicating it is safe to use in celiac patients.